Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

BVS

Bioventus Inc

Oct 08 • 02:24PM ET

11.50

Dollar change +0.31
Percentage change 2.74	%

Healthcare • Medical Devices • USA • NASD

Held by: IWM VTI AVUV VXF DWAS IWN SCHA VTWO FESM IWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.66	Insider Own	37.54%	Shs Outstand	63.27M	Perf Week	-2.48%
Market Cap	749.50M	Forward P/E	17.78	EPS next Y	0.65	Insider Trans	0.19%	Shs Float	40.72M	Perf Month	9.50%
Income	-41.96M	PEG	-	EPS next Q	0.02	Inst Own	39.58%	Short Float	3.37%	Perf Quarter	95.20%
Sales	536.89M	P/S	1.40	EPS this Y	1845.00%	Inst Trans	-15.77%	Short Ratio	2.38	Perf Half Y	127.22%
Book/sh	2.32	P/B	4.96	EPS next Y	66.21%	ROA	-5.15%	Short Interest	1.37M	Perf Year	267.32%
Cash/sh	0.49	P/C	23.43	EPS next 5Y	-	ROE	-25.12%	52W Range	2.85 - 12.41	Perf YTD	118.16%
Dividend Est.	-	P/FCF	103.24	EPS past 5Y	-51.10%	ROI	-8.32%	52W High	-7.36%	Beta	0.92
Dividend TTM	-	Quick Ratio	0.96	Sales past 5Y	10.81%	Gross Margin	64.99%	52W Low	303.41%	ATR (14)	0.55
Dividend Ex-Date	Mar 26, 2004	Current Ratio	1.33	EPS Y/Y TTM	85.57%	Oper. Margin	4.31%	RSI (14)	57.60	Volatility	3.76% 4.92%
Employees	970	Debt/Eq	2.62	Sales Y/Y TTM	5.14%	Profit Margin	-7.82%	Recom	2.33	Target Price	12.33
Option/Short	Yes / Yes	LT Debt/Eq	2.34	EPS Q/Q	-536.90%	Payout	-	Rel Volume	0.51	Prev Close	11.19
Sales Surprise	9.90%	EPS Surprise	182.74%	Sales Q/Q	10.32%	Earnings	Aug 06 BMO	Avg Volume	577.75K	Price	11.50
SMA20	0.45%	SMA50	17.74%	SMA200	77.11%	Trades		Volume	224,137	Change	2.74%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-07-23	Upgrade	Canaccord Genuity	Hold → Buy	$7
Aug-09-23	Upgrade	Craig Hallum	Hold → Buy	$4 → $6
Nov-22-22	Downgrade	Craig Hallum	Buy → Hold
Nov-09-22	Downgrade	JP Morgan	Overweight → Underweight
Nov-09-22	Downgrade	Canaccord Genuity	Buy → Hold	$18 → $6
Mar-15-22	Initiated	Craig Hallum	Buy	$30
Nov-15-21	Resumed	Morgan Stanley	Overweight	$20
Nov-10-21	Resumed	JP Morgan	Overweight	$25
Jul-01-21	Downgrade	Goldman	Buy → Neutral	$20 → $19
Mar-08-21	Initiated	Morgan Stanley	Overweight	$18
Mar-08-21	Initiated	JP Morgan	Overweight	$17
Mar-08-21	Initiated	Goldman	Buy	$19
Mar-08-21	Initiated	Canaccord Genuity	Buy	$23

Show Previous Ratings

Oct-01-24 09:00AM	Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners (GlobeNewswire)
Aug-29-24 07:09AM	Bull Of The Day: Bioventus (BVS) (Zacks)
Aug-07-24 04:15PM	Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference (GlobeNewswire) -7.79%
Aug-06-24 07:30AM	Bioventus Reports Second Quarter Financial Results (GlobeNewswire) +29.23%
Jul-30-24 07:30AM	Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024 (GlobeNewswire)
10:17AM	Loading…
Jun-05-24 10:17AM	Here's Why You Should Consider Buying Bioventus (BVS) Stock (Zacks)
May-23-24 06:42AM	3 Stocks Under $10 With Mammoth Growth Prospects (InvestorPlace)
May-09-24 07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +8.33%
May-08-24 12:28PM	Bioventus Inc. (NASDAQ:BVS) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:19AM	Bioventus Inc (BVS) Q1 2024 Earnings Call Transcript Highlights: Strong Start with Significant ... (GuruFocus.com)
May-07-24 11:41PM	Q1 2024 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents) +28.00%
07:00AM	Bioventus Reports First Quarter Financial Results (GlobeNewswire)
Apr-29-24 07:30AM	Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Mar-13-24 08:48AM	Bioventus Inc. (NASDAQ:BVS) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.54%
Mar-12-24 10:20PM	Q4 2023 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents) +5.46%
09:11AM	Loading…
09:11AM	Bioventus Inc (BVS) Reports Growth in Q4 Sales and Adjusted EBITDA, Provides Optimistic 2024 ... (GuruFocus.com)
07:30AM	Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-04-24 08:00AM	Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024 (GlobeNewswire)
Jan-18-24 04:15PM	Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility (GlobeNewswire)
Jan-12-24 04:15PM	Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole (GlobeNewswire)
Dec-19-23 04:30PM	Bioventus Names Robert Claypoole as President and Chief Executive Officer (GlobeNewswire)
Dec-06-23 08:00AM	Bioventus Agrees to Nationwide Contract with Aetna Medicare Advantage Plans for DUROLANE for Knee Osteoarthritis (GlobeNewswire)
Nov-27-23 01:33AM	Smith & Nephew inks $180M CartiHeal buyout, capitalizing on Bioventus turmoil to land knee implant (MedTech Dive)
Nov-12-23 09:02AM	Bioventus Inc. (NASDAQ:BVS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 07:59AM	Bioventus Inc (BVS) Reports Q3 2023 Financial Results, Raises Full Year 2023 Financial Guidance (GuruFocus.com)
07:00AM	Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance (GlobeNewswire)
Oct-31-23 07:00AM	Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023 (GlobeNewswire) +5.37%
Oct-25-23 10:48AM	Bioventus (BVS) to Report Q3 Earnings: What's in the Cards? (Zacks)
Sep-28-23 07:43AM	3 Value Medical Stocks to Buy for Safety Amid Market Volatility (Zacks)
Sep-19-23 09:52PM	Bioventus to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
04:30PM	Loading…
Sep-06-23 04:30PM	Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-16-23 09:02AM	Juniper Investment Company, LLC Increases Stake in Bioventus Inc (GuruFocus.com) -5.26%
Aug-10-23 08:09AM	Bioventus works to trim debt under interim CEO (American City Business Journals) +11.74%
Aug-08-23 10:02PM	Q2 2023 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents) +14.12% +5.41%
07:30AM	Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance (GlobeNewswire)
Aug-04-23 08:30AM	Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference (GlobeNewswire)
Aug-01-23 05:35PM	Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Jun-23-23 06:35PM	Madrigal Pharmaceuticals and Bioventus Stock See Action From Activist Investors (Barrons.com) -7.02%
May-25-23 06:38AM	Daily Vickers Top Buyers & Sellers for 05/25/2023 (Argus Research)
May-23-23 07:30AM	Bioventus Completes Divestiture of its Wound Business (GlobeNewswire) +16.27%
May-18-23 12:07PM	Bioventus Inc. (NASDAQ:BVS) Q1 2023 Earnings Call Transcript (Insider Monkey) +11.45%
May-17-23 08:33AM	Q1 2023 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents) +9.17%
May-16-23 04:15PM	Bioventus Reports First Quarter Financial Results (GlobeNewswire)
May-15-23 05:33PM	Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023 (GlobeNewswire)
May-11-23 07:00AM	Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023 (GlobeNewswire) +17.48%
May-10-23 09:00AM	Bioventus Announces Divestiture of its Wound Business (GlobeNewswire) +6.95%
May-03-23 08:30AM	Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023 (GlobeNewswire)
Apr-08-23 08:55AM	While institutions invested in Bioventus Inc. (NASDAQ:BVS) benefited from last week's 22% gain, private equity firms stood to gain the most (Simply Wall St.)
Apr-05-23 10:52AM	Bioventus Inc. (NASDAQ:BVS) Q4 2022 Earnings Call Transcript (Insider Monkey) +12.73%
08:00AM	Bioventus Announces CEO Leadership Change (GlobeNewswire)
07:38AM	New Strong Sell Stocks for April 5th (Zacks)
Mar-31-23 07:30AM	Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results (GlobeNewswire) -11.57%
07:00AM	Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility (GlobeNewswire)
Mar-30-23 04:51AM	Heres Why Bioventus (BVS) Declined in Q4 (Insider Monkey)
Mar-29-23 08:55AM	Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023 (GlobeNewswire)
Mar-20-23 10:16AM	Are Options Traders Betting on a Big Move in Bioventus (BVS) Stock? (Zacks)
Mar-16-23 08:30AM	Bioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023 (GlobeNewswire) -12.88%
Feb-28-23 07:30AM	Bioventus Enters into Settlement Agreement to Preserve Maximum Optionality Up To $350mm of Potential Liability Reduction and a Release of Future Claims related to the CartiHeal Acquisition (GlobeNewswire) +45.89%
Jan-27-23 02:49PM	Bioventus to divest assets ahead of major payments coming due (American City Business Journals)
Jan-14-23 03:14PM	15 Largest Orthopedic Companies in the World (Insider Monkey)
Jan-04-23 07:00AM	Bioventus to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-22 02:53PM	2022 Year in Review: Layoffs hit Triangle biotech, pharma companies (American City Business Journals)
Dec-09-22 11:58AM	Durham's Bioventus slashing headcount to rein in expenses (American City Business Journals)
Nov-28-22 10:34PM	Why this Durham firm's stock is down more than 70% this month (American City Business Journals) -20.41%
Nov-21-22 05:15PM	Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance (GlobeNewswire)
Nov-16-22 05:15PM	Bioventus Files for Extension to File Form 10-Q for the Period Ended October 1, 2022 (GlobeNewswire) -9.45% -33.67%
Nov-10-22 05:38AM	Bioventus Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.) +25.58%
Nov-09-22 06:18PM	Why Shares of Bioventus Fell 14% on Wednesday (Motley Fool) -14.00%
Nov-08-22 07:30AM	Bioventus Reports Third Quarter Results; Updates Full-Year 2022 Financial Guidance (GlobeNewswire) -57.51%
Oct-31-22 07:00AM	Bioventus to Report Third Quarter of Fiscal Year 2022 Financial Results on November 8, 2022 (GlobeNewswire)
Oct-12-22 08:00AM	Bioventus to Showcase Full Orthobiologics and Ultrasonic Portfolio at NASS in Chicago (GlobeNewswire)
Aug-30-22 08:00AM	Bioventus to Present at the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-12-22 02:32AM	Bioventus Inc. (BVS) Q2 2022 Earnings Call Transcript (Motley Fool) +7.84%
Aug-11-22 07:00AM	Bioventus Reports Second Quarter Results; Updates Full-Year 2022 Financial Guidance (GlobeNewswire)
Aug-03-22 07:00AM	Bioventus Receives FDA 510(k) Clearance for SonaStar Elite (GlobeNewswire)
Jul-26-22 07:00AM	Bioventus to Report Second Quarter of Fiscal Year 2022 Financial Results on August 11, 2022 (GlobeNewswire)
Jul-12-22 08:30AM	Bioventus Completes CartiHeal Acquisition (GlobeNewswire) +9.67%
Jul-04-22 10:00AM	Investors one-year losses grow to 57% as the stock sheds US$66m this past week (Simply Wall St.)
Jun-22-22 05:00AM	Durham firm reworks $450M acquisition amid stock market volatility (American City Business Journals)
Jun-21-22 07:30AM	Bioventus Amends CartiHeal Acquisition Structure (GlobeNewswire) -5.04%
Jun-15-22 08:33AM	Implied Volatility Surging for Bioventus (BVS) Stock Options (Zacks)
May-10-22 01:00PM	Bioventus Inc. (BVS) Q1 2022 Earnings Call Transcript (Motley Fool)
07:00AM	Bioventus Reports First Quarter Results; Reaffirms Full-Year 2022 Financial Guidance (GlobeNewswire)
May-04-22 02:54PM	With markets shaky, Durham firm scraps $415M plan to fund acquisition (American City Business Journals) -10.41%
05:56AM	U.K. Companies Borrowing Costs Surge Past Covid-19 Pandemic Peak (Bloomberg)
May-03-22 05:47PM	Bioventus Cancels Proposed $415 Million Offering of Senior Notes; Reaffirms Full-Year 2022 Financial Guidance (GlobeNewswire)
01:57PM	Fearful Investors Should Buy Credit, Sell Stocks, JPMorgan Says (Bloomberg)
May-02-22 07:00AM	Bioventus Agrees to Nationwide Contract with Cigna Commercial Plans for DUROLANE® and GELSYN-3® for Knee Osteoarthritis (GlobeNewswire) -8.56%
Apr-26-22 02:59PM	Durham company needs to raise $415M for deal. Here's how it's doing it. (American City Business Journals)
09:05AM	Bioventus Announces Preliminary First Quarter Net Sales and Adjusted EBITDA (GlobeNewswire)
08:38AM	Bioventus Announces $415 Million Offering of Senior Notes (GlobeNewswire)
Apr-25-22 07:00AM	Bioventus to Report First Quarter of Fiscal Year 2022 Financial Results on May 10, 2022 (GlobeNewswire)
Apr-08-22 09:15AM	Bioventus TheraSkin Coverage Expands to Provide for 17 Million More Covered Lives (GlobeNewswire)
Apr-07-22 10:12PM	Some Investors May Be Worried About Bravura Solutions' (ASX:BVS) Returns On Capital (Simply Wall St.)
Apr-05-22 07:00AM	Bioventus Announces Inducement Equity to SVP Chief Financial Officer Mark Singleton (GlobeNewswire)
Apr-04-22 05:36PM	Bioventus Inc. (NASDAQ:BVS) Shares Could Be 47% Below Their Intrinsic Value Estimate (Simply Wall St.)
02:23PM	Durham public company adds to acquisition streak with $450M deal (American City Business Journals)
11:27AM	Why Bioventus Stock Is Sinking Today (Motley Fool)
07:00AM	Bioventus Exercises Call Option to Acquire CartiHeal (GlobeNewswire)
Apr-03-22 09:10PM	3 Strong Buy Stocks to Watch as 2Q22 Kicks Off (TipRanks)

Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bartholdson John A.	Director	Aug 16 '24	Buy	8.55	80,000	683,736	6,913,857	Aug 20 06:16 PM
Bartholdson John A.	Director	Aug 19 '24	Buy	8.55	25,500	217,966	6,939,357	Aug 20 06:16 PM
Singleton Mark Leonard	SVP & CFO	Jun 21 '24	Sale	5.57	9,219	51,350	84,895	Jun 25 04:59 PM
D'Adamio Anthony	SVP & General Counsel	Jun 21 '24	Sale	5.57	5,904	32,885	95,576	Jun 25 04:58 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Jun 21 '24	Sale	5.57	2,559	14,254	41,199	Jun 25 04:58 PM
Singleton Mark Leonard	SVP & CFO	Jun 20 '24	Option Exercise	0.00	31,000	0	94,114	Jun 24 08:46 PM
D'Adamio Anthony	SVP & General Counsel	Jun 20 '24	Option Exercise	0.00	19,850	0	101,480	Jun 24 08:45 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Jun 20 '24	Option Exercise	0.00	8,600	0	43,758	Jun 24 08:45 PM
Singleton Mark Leonard	SVP & CFO	Jun 17 '24	Sale	5.84	13,753	80,318	63,114	Jun 21 04:27 PM
D'Adamio Anthony	SVP & General Counsel	Jun 17 '24	Sale	5.84	11,308	66,039	81,630	Jun 21 04:25 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Jun 17 '24	Sale	5.84	8,759	51,153	35,158	Jun 21 04:24 PM
McMurry-Heath Michelle	Director	Jun 16 '24	Option Exercise	0.00	386	0	48,205	Jun 18 05:44 PM
Ladone Mary Kay	Director	Jun 16 '24	Option Exercise	0.00	1,814	0	52,488	Jun 18 05:43 PM
Beyer Pat	Director	Jun 16 '24	Option Exercise	0.00	965	0	49,943	Jun 18 05:43 PM
Singleton Mark Leonard	SVP & CFO	Jun 15 '24	Option Exercise	0.00	42,202	0	76,867	Jun 18 05:42 PM
D'Adamio Anthony	SVP & General Counsel	Jun 15 '24	Option Exercise	0.00	34,696	0	92,938	Jun 18 05:40 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Jun 15 '24	Option Exercise	0.00	26,875	0	43,917	Jun 18 05:40 PM
SUTTER MARTIN P	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	58,748	Jun 11 08:47 PM
STALNECKER SUSAN M	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	79,464	Jun 11 08:46 PM
NOHRA GUY P	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	100,117	Jun 11 08:46 PM
NEELS GUIDO J	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	58,748	Jun 11 08:45 PM
HAWKINS WILLIAM A	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	231,358	Jun 11 08:45 PM
Ladone Mary Kay	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	50,674	Jun 11 08:44 PM
McMurry-Heath Michelle	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	47,819	Jun 11 08:44 PM
Beyer Pat	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	48,978	Jun 11 08:43 PM
Bartholdson John A.	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	45,552	Jun 11 08:43 PM
Bartholdson John A.	Director	Jun 06 '24	Option Exercise	0.00	7,576	0	15,152	Jun 10 05:40 PM
Singleton Mark Leonard	SVP & CFO	Apr 11 '24	Sale	4.75	4,000	19,000	34,665	Apr 15 06:03 PM
D'Adamio Anthony	SVP & General Counsel	Apr 11 '24	Sale	4.75	3,054	14,506	58,242	Apr 15 06:00 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Apr 11 '24	Sale	4.75	1,325	6,294	17,042	Apr 15 05:58 PM
Singleton Mark Leonard	SVP & CFO	Mar 22 '24	Sale	5.39	5,541	29,853	25,665	Mar 25 05:36 PM
D'Adamio Anthony	SVP & General Counsel	Mar 15 '24	Sale	5.46	3,125	17,062	51,371	Mar 20 06:41 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Mar 15 '24	Sale	5.46	1,217	6,645	14,067	Mar 20 06:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BVS

Bioventus Inc

Upgrade your FINVIZ experience